Literature DB >> 33830787

Accounting for All Patients in Waterfall Plots.

James Moon1, Michael LeBlanc1, Megan Othus1.   

Abstract

Entities:  

Year:  2021        PMID： 33830787      PMCID： PMC8240789          DOI： 10.1200/CCI.20.00150

Source DB:  PubMed          Journal:  JCO Clin Cancer Inform        ISSN： 2473-4276


× No keyword cloud information.
  9 in total

1.  Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.

Authors:  Mark J Ratain; Tim Eisen; Walter M Stadler; Keith T Flaherty; Stan B Kaye; Gary L Rosner; Martin Gore; Apurva A Desai; Amita Patnaik; Henry Q Xiong; Eric Rowinsky; James L Abbruzzese; Chenghua Xia; Ronit Simantov; Brian Schwartz; Peter J O'Dwyer
Journal:  J Clin Oncol       Date:  2006-04-24       Impact factor: 44.544

2.  Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.

Authors:  Julien Mazières; Gérard Zalcman; Lucio Crinò; Pamela Biondani; Fabrice Barlesi; Thomas Filleron; Anne-Marie C Dingemans; Hervé Léna; Isabelle Monnet; Sacha I Rothschild; Federico Cappuzzo; Benjamin Besse; Luc Thiberville; Damien Rouvière; Rafal Dziadziuszko; Egbert F Smit; Jurgen Wolf; Christian Spirig; Nicolas Pecuchet; Frauke Leenders; Johannes M Heuckmann; Joachim Diebold; Julie D Milia; Roman K Thomas; Oliver Gautschi
Journal:  J Clin Oncol       Date:  2015-02-09       Impact factor: 44.544

3.  Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.

Authors:  James Larkin; Christopher D Lao; Walter J Urba; David F McDermott; Christine Horak; Joel Jiang; Jedd D Wolchok
Journal:  JAMA Oncol       Date:  2015-07       Impact factor: 31.777

4.  Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials.

Authors:  Howard L West; James Moon; Antoinette J Wozniak; Philip Mack; Fred R Hirsch; Martin J Bury; Myron Kwong; Dorothy D Nguyen; Dennis F Moore; Jieling Miao; Mary Redman; Karen Kelly; David R Gandara
Journal:  Clin Lung Cancer       Date:  2017-07-06       Impact factor: 4.785

5.  MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

Authors:  Paolo A Ascierto; Dirk Schadendorf; Carola Berking; Sanjiv S Agarwala; Carla Ml van Herpen; Paola Queirolo; Christian U Blank; Axel Hauschild; J Thaddeus Beck; Annie St-Pierre; Faiz Niazi; Simon Wandel; Malte Peters; Angela Zubel; Reinhard Dummer
Journal:  Lancet Oncol       Date:  2013-02-13       Impact factor: 41.316

6.  Use and misuse of waterfall plots.

Authors:  Tiffany Shao; Lisa Wang; Arnoud J Templeton; Raymond Jang; Francisco W Vera-Badillo; Mairead G McNamara; Myles Margolis; Tae Kyoung Kim; Mehrdad Sinaei; Hassan Shoushtari; Ian F Tannock
Journal:  J Natl Cancer Inst       Date:  2014-10-29       Impact factor: 13.506

7.  Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438).

Authors:  Kim A Margolin; James Moon; Lawrence E Flaherty; Christopher D Lao; Wallace L Akerley; Megan Othus; Jeffrey A Sosman; John M Kirkwood; Vernon K Sondak
Journal:  Clin Cancer Res       Date:  2012-01-06       Impact factor: 12.531

8.  A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors.

Authors:  Sandip P Patel; Young Kwang Chae; Megan Othus; Francis J Giles; Donna E Hansel; Preet Paul Singh; Annette Fontaine; Manisha H Shah; Anup Kasi; Tareq Al Baghdadi; Marc Matrana; Zoran Gatalica; W Michael Korn; Jourdain Hayward; Christine McLeod; Helen X Chen; Elad Sharon; Edward Mayerson; Christopher W Ryan; Melissa Plets; Charles D Blanke; Razelle Kurzrock
Journal:  Clin Cancer Res       Date:  2020-01-22       Impact factor: 12.531

9.  Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512.

Authors:  Shailender Bhatia; James Moon; Kim A Margolin; Jeffrey S Weber; Christopher D Lao; Megan Othus; Ana M Aparicio; Antoni Ribas; Vernon K Sondak
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.